How many insider trades does FilingIQ track for KYMR?

FilingIQ tracks 613 Form 4 insider transactions for KYMR (Kymera Therapeutics, Inc.), covering filings from Aug 21, 2020 onwards. 122 of those were filed in the last 90 days.

Are KYMR insiders net buyers or net sellers?

Across the full Form 4 history for KYMR, 45 transactions (7%) were open-market purchases and 355 (58%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does KYMR insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is KYMR in?

Kymera Therapeutics, Inc. (KYMR) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $6.99B.

KYMR insider trading

NasdaqGM Healthcare

Kymera Therapeutics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

613

Last 90 days

122

Buys / sells

7% / 58%

Market cap

$6.99B

About Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis. The company also develops STAT6, a type 2 inflammation in allergic and atopic diseases; and TYK2 to treat autoimmune and inflammatory diseases. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside of the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Company website: www.kymeratx.com

KYMR insider activity at a glance

FilingIQ has scored 613 insider transactions for KYMR since Aug 21, 2020. The most recent filing in our index is dated May 11, 2026.

Across the full history, 45 open-market purchases and 355 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on KYMR insider trades is 55.5/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live KYMR trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

13F funds holding KYMR

Avoro Capital Advisors LLC

$581.61M · 5.7% of AUM

Artal Group S.A.

$121.69M · 3.1% of AUM

Siren, L.L.C.

$88.69M · 5.0% of AUM

Yiheng Capital Management, L.P.

$3.36M · 0.3% of AUM

Frequently asked

How many insider trades does FilingIQ track for KYMR?: FilingIQ tracks 613 Form 4 insider transactions for KYMR (Kymera Therapeutics, Inc.), covering filings from Aug 21, 2020 onwards. 122 of those were filed in the last 90 days.
Are KYMR insiders net buyers or net sellers?: Across the full Form 4 history for KYMR, 45 transactions (7%) were open-market purchases and 355 (58%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does KYMR insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is KYMR in?: Kymera Therapeutics, Inc. (KYMR) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $6.99B.

Methodology & sources

Every KYMR insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.